Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Daniel Wojenski
Observed names:
D.J. Wojenski,
Daniel J. Wojenski,
Daniel Jerzy Wojenski
Institutions:
Northwestern University,
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Observed institutions:
Northwestern University,
Mayo Clinic,
Northwestern Medicine,
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
OpenAlex ID:
A5075537115
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
2020
·
Anthony R. Mato
, Lindsey E. Roeker
, et al.
·
Blood
·
305
PDF
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
2021
·
Lindsey E. Roeker
, Toby A. Eyre
, et al.
·
Blood
·
66
PDF
Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients
2015
·
D.J. Wojenski
, G.T. Bartoo
, et al.
·
Transplant Infectious Disease
·
35
Cefpodoxime for Antimicrobial Prophylaxis in Neutropenia: A Retrospective Case Series
2014
·
Daniel J. Wojenski
, Jason N. Barreto
, et al.
·
Clinical Therapeutics
·
19
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
2020
·
Lindsey E Roeker
, Lydia Scarfo
, et al.
·
Blood
·
4
Voriconazole Exposure and the Risk of Cutaneous Squamous Cell Carcinoma in Allogeneic Hematopoietic Stem Cell Transplant Patients
2014
·
Shahrukh Hashmi
, Daniel Wojenski
, et al.
·
Transplantation and Cellular Therapy
·
1
PDF
Venetoclax in Combination with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Is Comparable to Alternative Regimens
2020
·
Jenn Miller
, Lindsey Shannon
, et al.
·
Blood
CDEA for Peripheral Blood Stem Cell Mobilization
2016
·
Soniya Tambe
, Daniel Wojenski
, et al.
·
Transplantation and Cellular Therapy
Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients
2013
·
Shahrukh K Hashmi
, Daniel Wojenski
, et al.
·
Blood
Comparison of toxicity, efficacy, and dose modifications in obese and non-obese patients receiving modified FOLFOX6 (mFOLFOX) for metastatic colorectal cancer (mCRC).
2013
·
Daniel Jerzy Wojenski
, Heidi D. Finnes
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
10
Citation count:
430
H-index:
4
I10-index:
4
Year
Topic
Type